resmetirom

Sponsor Madrigal Pharmaceuticals, INC. · listed as MDGL

READOUT Phase 3 Confidence: medium Source: clinicaltrials

resmetirom is a clinical-stage drug asset sponsored by Madrigal Pharmaceuticals, INC., listed as MDGL. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Mar 2027 (month precision, medium confidence), tied to trial NCT04951219. The asset is in Phase 3 and currently active not recruiting, studied in Non-Alcoholic Fatty Liver Disease. It appears across 3 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-03-31

As disclosedMar 2027

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT04951219

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorMadrigal Pharmaceuticals, Inc.

Listed asMDGL

Condition(s)Non-Alcoholic Fatty Liver Disease

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More MDGL catalysts